{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:06:17Z","timestamp":1789239977908,"version":"build-2803163510"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>This case series records a cohort of patients treated with transdermal buprenorphine patches as part of a buprenorphine microdose induction protocol to transition from methadone to buprenorphine in a community setting. This has historically been a difficult process to manage in community settings and this case series explored a method to gradually manage this in an outpatient setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A retrospective file audit was conducted of the electronic medical records of cohealth Innerspace patients who had undergone buprenorphine microdose induction using transdermal patches. A total of 32 patients were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this case series 23 of the 32 patients successfully transitioned from methadone to sublingual or long\u2010acting injectable depot buprenorphine preparations utilising the transdermal buprenorphine microdosing technique. All patients in this case series regardless of the success of the transition were retained in treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusions<\/jats:title><jats:p>A fixed\u2010dose transdermal buprenorphine patch regimen enabled 23 of 32 patients in this case series transition from methadone to buprenorphine in an outpatient setting. Given the small sample size further research is required to demonstrate the effectiveness of this technique.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dar.13826","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:39:41Z","timestamp":1708994381000},"page":"1013-1018","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Buprenorphine microdosing regimen using transdermal buprenorphine patches to transition from methadone to buprenorphine"],"prefix":"10.1111","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0887-3696","authenticated-orcid":false,"given":"Thileepan","family":"Naren","sequence":"first","affiliation":[{"name":"Drug Health Services, Western Health  Melbourne Australia"},{"name":"cohealth Innerspace  Melbourne Australia"},{"name":"Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Cook","sequence":"additional","affiliation":[{"name":"Drug Health Services, Western Health  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"MacCartney","sequence":"additional","affiliation":[{"name":"Drug Health Services, Western Health  Melbourne Australia"},{"name":"cohealth Innerspace  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Membrey","sequence":"additional","affiliation":[{"name":"Drug Health Services, Western Health  Melbourne Australia"},{"name":"cohealth Innerspace  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"National guidelines for medication\u2010assisted treatment of opioid dependence.2014."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.718811"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000855"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.91934"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246290"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S109919"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2020.106740"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.74018"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.631784"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-020-0177-x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10071307"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/19.124"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2011.00159.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004311"},{"key":"e_1_2_8_16_1","volume-title":"Australian product information\u2014Norspan\u00ae (buprenorphine) transdermal drug delivery system (Patch)","year":"2022"},{"key":"e_1_2_8_17_1","unstructured":"Care AGD of H and A.Pharmaceutical Benefits Scheme (PBS) | buprenorphine transdermal patch 5 mg 10 mg and 20 mg (releasing 5 micrograms 10 micrograms and 20 micrograms per hour respectively) Norspan\u00ae July 2005. [Internet]. Australian Government Department of Health and Aged Care; [cited 20 November 2022]. Available from:https:\/\/www.pbs.gov.au\/pbs\/industry\/listing\/elements\/pbac-meetings\/psd\/2005-07\/buprenorphine"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.13826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T09:22:46Z","timestamp":1715937766000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.13826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/dar.13826"],"URL":"https:\/\/doi.org\/10.1111\/dar.13826","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"2023-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}